Fundamentals of Atherogenesis Flashcards

1
Q

what is atherosclerosis?

A

Is the principal cause of heart attack, stroke and gangrene of the extremities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the main problem of atherosclerosis?

A

is plaque rupture leading to thrombus formation, partial/complete arterial blockage leading to a heart attack

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the risk factors For Atherosclerosis?

A

Age
Tobacco Smoking
High Serum Cholesterol
Obesity
Diabetes
Hypertension
Family History

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

which is the best-known risk factor for coronary artery disease
1. Obesity
2. Diabetes
3. Gender
4. Age

A

AGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

where are atherosclerosis plaques distributed?

A

Found within peripheral and coronary arteries
Focal distribution along the artery length

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe how Distribution may be governed by haemodynamic factors

A

Changes in flow/turbulence (eg at bifurcations) cause the artery to alter endothelial cell function. Wall thickness is also changed leading to neointima. Altered gene expression in the key cell types is key.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Q: Which of the following is not in artery walls?
1.Tunica intima
2.Tunica media
3.Epithelial cells
4.Neutrophils

A

EPITHELIAL CELLS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what does an atherosclerotic plaque consist of:

A
  • Lipid
    -Necrotic core
    -Connective tissue
    -Fibrous “cap”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what will the plaque eventually do to the vessel?

A

will either occlude the vessel lumen resulting in a restriction of blood flow (angina), or it may “rupture” (thrombus formation – death).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what initiates atherosclerosis?

A
  1. Initiated by an injury to the endothelial cells which leads to endothelial dysfunction.
    2.Signals sent to circulating leukocytes which then accumulate and migrate into the vessel wall.
  2. Inflammation ensues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

name 4 examples of good inflammation

A

Pathogens
Parasites
Tumors
Wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

name 8 examples of bad inflammation

A

Myocardial reperfusion injury
Atherosclerosis
Ischaemic heart disease
Rheumatoid arthritis
Asthma
Inflammatory bowel disease
Shock
Excessive wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what ignites inflammation in the arterial wall?

A

LDL
Endothelial dysfunction- in response to injury hypothesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what ignites inflammation in the arterial wall-LDL?

A

can pass in and out of the arterial wall
in excess it accumulates in arterial wall, and undergoes oxidation and glycation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

once inflammation is initiated what occurs to the chemoattractants?

A

are released from endothelium and send signals to leukocytes.

AND/OR

are released from site of injury and a concentration-gradient is produced.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the inflammatory cytokines found in plaques

A

IL-1 - canakinumab
IL-6 – tocilizumab**
IL-8
IFN-g
TGF-b
MCP-1
(C reactive protein)

17
Q

Leukocyte recruitment to vessel walls - summary

A

capture
rolling
slow rolling
firm adhesion
transmigration

18
Q

describe the fatty streak stage of Progression of Atherosclerosis

A

-Earliest lesion of atherosclerosis
-Appear at a very early age (<10 years)
-Consist of aggregations of lipid–laden macrophages and T lymphocytes within the intimal layer of the vessel wall

19
Q

describe the intermediate lesions (2) stage of Progression of Atherosclerosis

A

Composed of layers of :
-Lipid laden macrophages (foam cells)

-Vascular smooth muscle cells

-T lymphocytes

-Adhesion and aggregation of platelets to vessel wall

-Isolated pools of extracellular lipid

20
Q

describe the fibrous plaques stage (3) of Progression of Atherosclerosis

A

Impedes blood flow
Prone to rupture
Covered by dense fibrous cap made of ECM proteins including collagen (strength) and elastin (flexibility) laid down by SMC that overlies lipid core and necrotic debris
May be calcified
Contains: smooth muscle cells, macrophages and foam cells and T lymphocytes

21
Q

describe the plaque rupture (4 )stage of Progression of Atherosclerosis

A

Plaques constantly grow and recede.
Fibrous cap has to be resorbed and redeposited in order to be maintained.
If balance shifted eg in favour of inflammatory conditions (increased enzyme activity), the cap becomes weak and the plaque ruptures.
Basement membrane, collagen, and necrotic tissue exposure as well as haemorrhage of vessels within the plaque
Thrombus (clot) formation and vessel occlusion

22
Q

describe the plaque erosion (5)stage of Progression of Atherosclerosis

A

-Second most prevalent cause of coronary thrombosis
-Lesions tend to be small ‘early lesions’
- A thickened fibrous cap may lead to collagen triggering thrombosis rather than tissue factor (as in plaque rupture)
- A platelet-rich clot may overlie the luminal surface.
-There is usually a small lipid core

23
Q

what are the treatments used for coronary artery disease?

A

PCI - Percutaneous Coronary Intervention

More than 90% of patients require stent implantation

Restenosis was a major limitation, no longer though due to drug eluting stents

24
Q

Q: What are coronary stents used in patients today made of?
1. Metal
2. Plastic
3. Polymers

A

metal

25
Q

describe aspirin

A

irreversible inhibitor of platelet cyclo-oxygenase

26
Q

describe Clopidogrel/Ticagrelor

A

inhibitors of the P2Y12 ADP receptor on platelets and other drugs with antiplatelet actions

27
Q

describe statins

A

inhibit HMG CoA reductase, reducing cholesterol synthesis

28
Q

describe PCSK9 inhibitors

A

monoclonal antibodies that inhibit PCSK9 protein in the liver which leads to improved clearance of cholesterol from the blood.